Globally, more than 58 million people are chronically infected with Hepatitis C virus (HCV)
with 1.5 million new infections occurring each year. An effective vaccine for HCV is therefore …

Introduction: With more than 150 million chronically infected people, hepatitis C virus (HCV)
remains a substantial global health burden. Direct-acting antivirals have dramatically …

The global fight against Human Immunodeficiency Virus (HIV) and related viral infections
stands at a pivotal juncture, demanding groundbreaking therapeutic strategies. Facing the …

There are 3‐4 million new hepatitis C virus (HCV) infections yearly. The extensive
intergenotypic sequence diversity of envelope proteins E1 and E2 of HCV and shielding of …

Multiple direct-acting antiviral (DAA)-based regimens are currently approved that provide
one or more interferon-free treatment options for hepatitis C virus (HCV) genotypes (G) 1–6 …

Highlights•HCV is a global health problem and a challenging vaccine target.•HCV actively
evades the immune response through high sequence variability.•Structural and amino acid …

The ability to use structure-based design and engineering to control the molecular shape
and reactivity of an immunogen to induce protective responses shows great promise, along …

The interplay between host antiviral immunity and immunopathology during hepatitis E virus
(HEV) infection determines important clinical outcomes. We characterized the specificity …

Retrovirus pseudotypes are a highly tractable model used to study the entry pathways of
enveloped viruses. This model has been extensively applied to the study of the hepatitis C …

Recent emergence of direct-acting antivirals (DAAs) targeting hepatitis C virus (HCV)
proteins has considerably enhanced the success of antiviral therapy. However, the …